Anixa CEO Amit Kumar purchases 5,000 shares

Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on 2026-07-20 at $3.46 per share in an open-market or private transaction.

Accepted by SEC EDGAR 07/21/2026 - 10:23 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on 2026-07-20 at $3.46 per share in an open-market or private transaction. Following this buy, he directly owns 640,812 shares. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider KUMAR AMIT

Role Chief Executive Officer

Bought 5,000 shs ($17K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$3.46	$17K

Holdings After Transaction: Common Stock — 640,812 shares (Direct)

Key Figures

Shares purchased: 5,000 shares Purchase price: $3.46 per share Total direct holdings after transaction: 640,812 shares +1 more

4 metrics

Shares purchased 5,000 shares Common Stock transaction on 2026-07-20

Purchase price $3.46 per share Price for the 5,000-share Common Stock purchase

Total direct holdings after transaction 640,812 shares Common Stock directly owned by Amit Kumar after the trade

Net buy shares in filing 5,000 shares Net buy direction per transactionSummary (net-buy)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Anixa Biosciences (ANIX) report in this Form 4?

Anixa Biosciences reported that CEO and director Amit Kumar purchased 5,000 shares of common stock on 2026-07-20 at $3.46 per share in a non-derivative, open-market or private transaction, increasing his directly held position.

How many Anixa Biosciences (ANIX) shares does CEO Amit Kumar now hold?

After the reported transaction, Amit Kumar directly owns 640,812 shares of Anixa Biosciences common stock. This total reflects his holdings immediately following the 5,000-share purchase disclosed in the Form 4 insider filing.

Was the Anixa Biosciences (ANIX) CEO trade made under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmed (aff_10b5_one is false), indicating the 5,000-share purchase by CEO Amit Kumar was not reported as being executed under a Rule 10b5-1 trading plan.

What type of security did Amit Kumar buy in this Anixa Biosciences (ANIX) Form 4?

Amit Kumar bought Common Stock in a non-derivative transaction. The Form 4 specifies a purchase of 5,000 shares of Anixa Biosciences common stock at $3.46 per share, rather than options or other derivative securities.

Is the reported Anixa Biosciences (ANIX) insider transaction a purchase or a sale?

It is a purchase. The Form 4 uses transaction code “P” and an acquired/disposed code of “A,” and the normalized direction fields classify the trade as a buy of 5,000 shares of common stock by CEO Amit Kumar.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/20/2026		P		5,000	A	$3.46	640,812	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amit Kumar	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)